| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | 0.073 | 0.07 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | 0.07 | 0.08 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | 0.066 | 0.08 |
| mRNA | KIN001-270 | GDSC1000 | pan-cancer | AAC | 0.063 | 0.08 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.067 | 0.08 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.065 | 0.08 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | 0.091 | 0.08 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | 0.09 | 0.08 |
| mRNA | importazole | CTRPv2 | pan-cancer | AAC | 0.072 | 0.08 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | 0.063 | 0.08 |